Nanobiotix - ADR opened lower at $31.94, compared with its previous close of $32.95. In the last trading session, the stock traded between $31.28 and $33.00. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Nanobiotix - ADR is now worth
$ 332.94
Giving a profit of
$ 232.94 (232.94%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
$-0.49 (-1.48%)
Day High
$33.00
Day Low
$31.28
Day Open
$31.94
Prev Close
$32.95
Volume
1,59,118
1W Return
9.51%
1M Return
40.86%
3M Return
-15.37%
6M Return
-39.38%
1Y Return
55.17%
Market Cap ($ Mn)
1,655
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-4,999.31%
EPS (TTM)
-
1 Week
9.51%
1 Month
40.86%
3 Months
-15.37%
6 Months
-39.38%
9 Months
34.59%
No data available.
Nanobiotix appoints Arnd Christ as chief financial officer
Arnd Christ appointed as CFO and executive board member effective October 1, 2026. Christ succeeds Bart Van Rhijn, who served for five years. Christ previously served as CFO of Immatics N.V. from October 2020 to September 2025. Appointment aligns with Nanobiotix's shift toward multi-platform strategy.
1mo agoNanobiotix Q2FY27 Results: Net loss widens to €34.3m on revenue drop
Net loss widened to €34.3 million in H1 2026 from €5.4 million in H1 2025. Revenue and other income dropped to €5.6 million from €26.6 million year-on-year. Cash position strengthened to €110.9 million as of June 30, 2026. R&D expenses decreased slightly to €12.7 million from €14.5 million. Lead candidate JNJ-1900 showed 79% locoregional control in Phase 1 NSCLC study.
1mo agoNanobiotix discloses 50,941,528 shares outstanding as of August 31, 2026
Shares outstanding total 50,941,528 as of August 31, 2026. Theoretical voting rights stand at 54,701,246. Exercisable voting rights are 54,679,128. Disclosure complies with French Commercial Code Article L.233-8 II.
1mo agoNanobiotix reports 70% one-year survival for JNJ-1900 in Phase 1 NSCLC trial
One-year overall survival reached 70% in Phase 1 NSCLC trial. No dose-limiting toxicities observed among 24 enrolled patients. Intratumoral injection deemed feasible with no drug-related Grade 3+ adverse events. Additional patient enrollment planned following completion of dose-escalation phase.
2mo agoNanobiotix to participate in H.C. Wainwright global investment conference
Nanobiotix plans to participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The event is scheduled for 12:00 pm EDT / 6:00 pm CEST in New York, NY. Presenters include Laurent Lévy, Chief Executive Officer, and Bart Van Rhijn, Chief Financial and Business Officer. Nanobiotix holds more than 30 umbrella patents across three nanotechnology platforms in oncology, bioavailability, and central nervous system disorders. The company is listed on Euronext Paris since 2012 and on Nasdaq since December 2020.
2mo agoNanobiotix reports 50.8 million shares outstanding as of July 31, 2026
Nanobiotix reported 50,833,462 shares outstanding as of July 31, 2026. Total theoretical voting rights stood at 54,534,179. Exercisable voting rights were recorded at 54,512,061. Disclosure complies with French Commercial Code and AMF regulations.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Nanobiotix - ADR is now worth
$ 332.94
Giving a profit of
$ 232.94 (232.94%)
Note: Past profits do not guarantee future returns.
